<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02658149</url>
  </required_header>
  <id_info>
    <org_study_id>2015-422</org_study_id>
    <nct_id>NCT02658149</nct_id>
  </id_info>
  <brief_title>Psoas Compartment Block Versus Periarticular Local Anesthetic for Total Hip Arthroplasty</brief_title>
  <official_title>Psoas Compartment Block Versus Periarticular Local Anesthetic Infiltration for Pain Management for Total Hip Arthroplasty: A Prospective, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Beaumont Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to examine whether there is a difference in the level
      of resting pain following total hip arthroplasty with an anterior approach with use of a
      psoas compartment block versus a local periarticular anesthetic infiltration
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-center, prospective, randomized clinical trial with a total of 100 patients. One
      orthopaedic adult reconstruction surgeon at Beaumont Hospital Royal Oak (JJV) will perform
      all surgeries. After the patient has consented they will be randomized to one of the
      following two groups:

        1. Psoas compartment block (n=50)

        2. Periarticular local anesthetic infiltration (n=50),

      The patient will be blinded to the study group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">June 2, 2017</completion_date>
  <primary_completion_date type="Actual">May 11, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score at 3 Hours</measure>
    <time_frame>3 hours postoperative</time_frame>
    <description>Visual Analog Scale 0-10; 0 = no pain, 10 = worst pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Score at 3-24 Hours</measure>
    <time_frame>measured once during time frame 3 hours-24 hours postoperative</time_frame>
    <description>Visual Analog Scale 0-10; 0 = no pain, 10 = worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score at 24-48 Hours</measure>
    <time_frame>measured once during time froma 24-48 hours postoperative</time_frame>
    <description>Visual Analog Scale 0-10; 0 = no pain, 10 = worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Usage In-hospital at 24 Hours</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Total amount of opioids used per patient (measured with Morphine Equivalent Units)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Usage In-hospital at 48 Hours</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>Total amount of opioids used per patient (measured with Morphine Equivalent Units)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Psoas Compartment Block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Periarticular Local Anesthetic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>An anesthetic &quot;cocktail&quot; of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine with NaCl</intervention_name>
    <description>50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment</description>
    <arm_group_label>Psoas Compartment Block</arm_group_label>
    <other_name>Naropin with NaCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>0.15 mg Epinephrine are injected as part of the drug &quot;cocktail&quot;</description>
    <arm_group_label>Periarticular Local Anesthetic</arm_group_label>
    <other_name>adrenaline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>4 mg Morphine are injected as part of the drug &quot;cocktail&quot;</description>
    <arm_group_label>Periarticular Local Anesthetic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Tromethamine</intervention_name>
    <description>30 mg morphine are injected as part of the drug &quot;cocktail&quot;</description>
    <arm_group_label>Periarticular Local Anesthetic</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>30 mL 0.5% Ropivicaine are injected as part of the drug &quot;cocktail&quot;</description>
    <arm_group_label>Periarticular Local Anesthetic</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing unilateral primary total hip arthroplasty by Dr. James Verner at
             Beaumont Hospital Royal Oak

          -  Have a diagnosis of primary osteoarthritis (i.e. degenerative joint disease)

          -  Surgical approach is anterior

        Exclusion Criteria:

          -  Minors (age less than 18 years)

          -  Pregnant (surgically sterile, post-menopausal, or negative blood test)

          -  Previous ipsilateral hip surgery

          -  Lumbar instrumentation

          -  Acute trauma

          -  Rheumatoid arthritis

          -  Avascular necrosis

          -  Hip dysplasia

          -  Known sensitivity, allergy, or contraindication to anesthetics being used in the study

          -  Narcotic sensitivity

          -  History of over 6 months of opioid dependency prior to surgery (excluding tramadol)

          -  Peripheral neuropathy

          -  Mental/cognitive impairment that would interfere with the patient's self-assessments
             of function, pain, or quality of life
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Verner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2016</study_first_posted>
  <results_first_submitted>February 16, 2018</results_first_submitted>
  <results_first_submitted_qc>April 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 9, 2018</results_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>James Verner</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Psoas Compartment Block</title>
          <description>After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).
Ropivacaine with NaCl: 50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment</description>
        </group>
        <group group_id="P2">
          <title>Periarticular Local Anesthetic</title>
          <description>An anesthetic &quot;cocktail&quot; of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues.
Epinephrine: 0.15 mg Epinephrine are injected as part of the drug &quot;cocktail&quot;
Morphine: 4 mg Morphine are injected as part of the drug &quot;cocktail&quot;
Ketorolac Tromethamine: 30 mg morphine are injected as part of the drug &quot;cocktail&quot;
Ropivacaine: 30 mL 0.5% Ropivicaine are injected as part of the drug &quot;cocktail&quot;</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Psoas Compartment Block</title>
          <description>After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).
Ropivacaine with NaCl: 50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment</description>
        </group>
        <group group_id="B2">
          <title>Periarticular Local Anesthetic</title>
          <description>An anesthetic &quot;cocktail&quot; of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues.
Epinephrine: 0.15 mg Epinephrine are injected as part of the drug &quot;cocktail&quot;
Morphine: 4 mg Morphine are injected as part of the drug &quot;cocktail&quot;
Ketorolac Tromethamine: 30 mg morphine are injected as part of the drug &quot;cocktail&quot;
Ropivacaine: 30 mL 0.5% Ropivicaine are injected as part of the drug &quot;cocktail&quot;</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="8"/>
                    <measurement group_id="B2" value="68" spread="8"/>
                    <measurement group_id="B3" value="67" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative Pain Score</title>
          <description>Visual Analog Pain Score; 0=no pain, 10=maximum pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.4" spread="2.5"/>
                    <measurement group_id="B2" value="2.5" spread="2.6"/>
                    <measurement group_id="B3" value="2.9" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Score at 3 Hours</title>
        <description>Visual Analog Scale 0-10; 0 = no pain, 10 = worst pain</description>
        <time_frame>3 hours postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psoas Compartment Block</title>
            <description>After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).
Ropivacaine with NaCl: 50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment</description>
          </group>
          <group group_id="O2">
            <title>Periarticular Local Anesthetic</title>
            <description>An anesthetic &quot;cocktail&quot; of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues.
Epinephrine: 0.15 mg Epinephrine are injected as part of the drug &quot;cocktail&quot;
Morphine: 4 mg Morphine are injected as part of the drug &quot;cocktail&quot;
Ketorolac Tromethamine: 30 mg morphine are injected as part of the drug &quot;cocktail&quot;
Ropivacaine: 30 mL 0.5% Ropivicaine are injected as part of the drug &quot;cocktail&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score at 3 Hours</title>
          <description>Visual Analog Scale 0-10; 0 = no pain, 10 = worst pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="2.2"/>
                    <measurement group_id="O2" value="2.9" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score at 3-24 Hours</title>
        <description>Visual Analog Scale 0-10; 0 = no pain, 10 = worst pain</description>
        <time_frame>measured once during time frame 3 hours-24 hours postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psoas Compartment Block</title>
            <description>After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).
Ropivacaine with NaCl: 50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment</description>
          </group>
          <group group_id="O2">
            <title>Periarticular Local Anesthetic</title>
            <description>An anesthetic &quot;cocktail&quot; of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues.
Epinephrine: 0.15 mg Epinephrine are injected as part of the drug &quot;cocktail&quot;
Morphine: 4 mg Morphine are injected as part of the drug &quot;cocktail&quot;
Ketorolac Tromethamine: 30 mg morphine are injected as part of the drug &quot;cocktail&quot;
Ropivacaine: 30 mL 0.5% Ropivicaine are injected as part of the drug &quot;cocktail&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score at 3-24 Hours</title>
          <description>Visual Analog Scale 0-10; 0 = no pain, 10 = worst pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.7"/>
                    <measurement group_id="O2" value="1.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.204</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score at 24-48 Hours</title>
        <description>Visual Analog Scale 0-10; 0 = no pain, 10 = worst pain</description>
        <time_frame>measured once during time froma 24-48 hours postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psoas Compartment Block</title>
            <description>After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).
Ropivacaine with NaCl: 50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment</description>
          </group>
          <group group_id="O2">
            <title>Periarticular Local Anesthetic</title>
            <description>An anesthetic &quot;cocktail&quot; of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues.
Epinephrine: 0.15 mg Epinephrine are injected as part of the drug &quot;cocktail&quot;
Morphine: 4 mg Morphine are injected as part of the drug &quot;cocktail&quot;
Ketorolac Tromethamine: 30 mg morphine are injected as part of the drug &quot;cocktail&quot;
Ropivacaine: 30 mL 0.5% Ropivicaine are injected as part of the drug &quot;cocktail&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score at 24-48 Hours</title>
          <description>Visual Analog Scale 0-10; 0 = no pain, 10 = worst pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.7"/>
                    <measurement group_id="O2" value="1.7" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Usage In-hospital at 24 Hours</title>
        <description>Total amount of opioids used per patient (measured with Morphine Equivalent Units)</description>
        <time_frame>24 hours postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psoas Compartment Block</title>
            <description>After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).
Ropivacaine with NaCl: 50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment</description>
          </group>
          <group group_id="O2">
            <title>Periarticular Local Anesthetic</title>
            <description>An anesthetic &quot;cocktail&quot; of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues.
Epinephrine: 0.15 mg Epinephrine are injected as part of the drug &quot;cocktail&quot;
Morphine: 4 mg Morphine are injected as part of the drug &quot;cocktail&quot;
Ketorolac Tromethamine: 30 mg morphine are injected as part of the drug &quot;cocktail&quot;
Ropivacaine: 30 mL 0.5% Ropivicaine are injected as part of the drug &quot;cocktail&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Usage In-hospital at 24 Hours</title>
          <description>Total amount of opioids used per patient (measured with Morphine Equivalent Units)</description>
          <units>Morphine Equivalent Units (Oral)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="12.8"/>
                    <measurement group_id="O2" value="16.7" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.741</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Usage In-hospital at 48 Hours</title>
        <description>Total amount of opioids used per patient (measured with Morphine Equivalent Units)</description>
        <time_frame>48 hours postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psoas Compartment Block</title>
            <description>After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).
Ropivacaine with NaCl: 50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment</description>
          </group>
          <group group_id="O2">
            <title>Periarticular Local Anesthetic</title>
            <description>An anesthetic &quot;cocktail&quot; of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues.
Epinephrine: 0.15 mg Epinephrine are injected as part of the drug &quot;cocktail&quot;
Morphine: 4 mg Morphine are injected as part of the drug &quot;cocktail&quot;
Ketorolac Tromethamine: 30 mg morphine are injected as part of the drug &quot;cocktail&quot;
Ropivacaine: 30 mL 0.5% Ropivicaine are injected as part of the drug &quot;cocktail&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Usage In-hospital at 48 Hours</title>
          <description>Total amount of opioids used per patient (measured with Morphine Equivalent Units)</description>
          <units>Morphine Equivalent Units (Oral)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" spread="16.8"/>
                    <measurement group_id="O2" value="20.8" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Psoas Compartment Block</title>
          <description>After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).
Ropivacaine with NaCl: 50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment</description>
        </group>
        <group group_id="E2">
          <title>Periarticular Local Anesthetic</title>
          <description>An anesthetic &quot;cocktail&quot; of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues.
Epinephrine: 0.15 mg Epinephrine are injected as part of the drug &quot;cocktail&quot;
Morphine: 4 mg Morphine are injected as part of the drug &quot;cocktail&quot;
Ketorolac Tromethamine: 30 mg morphine are injected as part of the drug &quot;cocktail&quot;
Ropivacaine: 30 mL 0.5% Ropivicaine are injected as part of the drug &quot;cocktail&quot;</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Prolonged transient numbness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations of this study include single surgeon and single institution data, which affects generalizability of results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. James Verner</name_or_title>
      <organization>Beaumont Health</organization>
      <phone>1(248)551-9722</phone>
      <email>jverner1@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

